Prothena Co. plc (NASDAQ:PRTA – Get Free Report) COO Brandon S. Smith sold 4,000 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $55.49, for a total value of $221,960.00. The sale was disclosed in a filing with the SEC, which is accessible […]
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) COO Brandon S. Smith sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $55.49, for a total transaction of $221,960.00. The sale was disclosed in a filing with the Securities & Exchange Commission, […]
Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Monday. A number of other analysts have also commented on PRTA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $129.00 price target on shares of Prothena in a […]
Guggenheim Capital LLC acquired a new position in Prothena Co. plc (NASDAQ:PRTA – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 17,390 shares of the biotechnology company’s stock, valued at approximately $843,000. A number of other large investors have […]
Oppenheimer & Co. Inc. purchased a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 1st quarter, Holdings Channel.com reports. The firm purchased 7,270 shares of the biotechnology company’s stock, valued at approximately $352,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the […]